# US 2024/0002811 A1 · Methods for Generation for Pluripotent and Multipotent Cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0002811 A1
- Document ID: US20240002811A1
- Status: Published application
- Kind: A1
- Application number: 18/320,244
- Filed: 2023-05-19
- Published: 2024-01-04
- Earliest claimed: 2012-04-09
- Assignees: The U.S.A., as represented by the Secretary, Department of Health and Human Services
- Applicants: The USA, as represented by the Secretary, Department of Health and Human Services
- Inventors: David D. Roberts; Sukhbir Kaur; Jeffrey S. Isenberg
- Web page: https://patentgrep.com/patent/US20240002811A1

## CPC

- C12N 5/0696: {Artificially induced pluripotent stem cells, e.g. iPS}
- C12N 5/0618: {Cells of the nervous system}
- C12N 5/0647: {Haematopoietic stem cells; Uncommitted or multipotent progenitors}
- C12N 2501/599: with CD designations not provided for elsewhere
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

This disclosure relates to methods of producing induced pluripotent (iPS), multipotent, and/or lineage-committed stem cells from differentiated cells, maintaining iPS, multipotent, and/or lineage-committed cells in culture, and re-differentiating the iPS and multipotent stem cells into any desired lineage-committed cell type.

## Claims

### Claim 1

A method for inducing pluripotent or multipotent stem cells, comprising:
obtaining primary cells from an animal;
culturing the primary cells; and
contacting the cultured primary cells with an agent that blocks CD47 signaling, thereby inducing pluripotent or multipotent stem cells.

### Claim 2 (depends on 1)

The method of claim 1, further comprising identifying and isolating a subset of pluripotent or multipotent stem cells that express stem cell marker genes.

### Claim 3 (depends on 2)

The method of claim 2, wherein the stem cell marker genes comprise at least one of c-Myc, Sox2, Klf4, or Oct4.

### Claim 4 (depends on 1)

The method of claim 1, further comprising culturing the primary cells in serum free media.

### Claim 5 (depends on 1)

The method of claim 1, wherein the induced pluripotent or multipotent stem cells form embryoid bodies.

### Claim 6 (depends on 1)

The method of claim 1, wherein the agent that blocks CD47 signaling comprises an anti-CD47 antibody or fragment thereof, a CD47-binding peptide, a CD47 antisense oligonucleotide, a CD47 morpholino, an anti-TSP1 antibody or fragment thereof, a TSP1-binding peptide, a TSP1 antisense oligonucleotide, or a TSP1 morpholino.

### Claim 7 (depends on 1)

The method of claim 1, wherein the agent comprises a small molecule capable of binding to CD47 or a small molecule capable of binding to TSP1.

### Claim 8 (depends on 1)

The method of claim 1, wherein the primary cells comprise endothelial cells, fibroblasts, hematopoietic cells, adipose cells, mucosal tissue cells, umbilical cord cells, or placenta cells.

### Claim 9 (depends on 8)

The method of claim 8, wherein the primary cells comprise human umbilical vein endothelial cells.

### Claim 10

A method for generating differentiated cells, comprising:
obtaining primary cells from an animal;
culturing the primary cells;
contacting the cultured primary cells with an agent that blocks CD47 signaling to produce contacted cells;
isolating from among the contacted cells, cells that express stem cell marker genes;
culturing the isolated cells that express stem cell marker genes in serum-free media to produce induced pluripotent or multipotent stem cells; and
culturing the induced pluripotent or multipotent stem cells in cell differentiation medium to produce differentiated cells.

### Claim 11 (depends on 10)

The method of claim 10, wherein the induced pluripotent or multipotent stem cells form embryoid bodies.

### Claim 12 (depends on 10)

The method of claim 10, wherein culturing the induced pluripotent or multipotent stem cells in cell differentiation medium comprises culturing the induced pluripotent or multipotent stem cells in neural cell differentiation medium, smooth muscle cell differentiation medium, hepatocyte cell differentiation medium, or mesenchymal cell differentiation medium.

### Claim 13 (depends on 1)

The method of claim 1, wherein the differentiated cells comprise ectoderm-derived lineage cells.

### Claim 14 (depends on 13)

The method of claim 13, wherein the ectoderm-derived lineage cells comprise neuronal cells or astrocytes.

### Claim 15 (depends on 1)

The method of claim 1, wherein the differentiated cells comprise mesoderm-derived lineage cells.

### Claim 16 (depends on 15)

The method of claim 15, wherein the mesoderm-derived lineage cells comprise smooth muscle cells, endothelial cells, hematopoietic cells, or myeloid cells.

### Claim 17 (depends on 1)

The method of claim 1, wherein the differentiated cells comprise endoderm-derived lineage cells.

### Claim 18 (depends on 17)

The method of claim 17, wherein the endoderm-derived lineage cells comprise hepatocytes or adipocytes.

### Claim 19 (depends on 1)

The method of claim 1, wherein the agent that blocks CD47 signaling comprises an anti-CD47 antibody or fragment thereof, a CD47-binding peptide, a CD47 antisense oligonucleotide, a CD47 morpholino, an anti-TSP1 antibody or fragment thereof, a TSP1-binding peptide, a TSP1 antisense oligonucleotide, or a TSP1 morpholino.

### Claim 20 (depends on 1)

The method of claim 1, wherein the agent comprises a small molecule capable of binding to CD47 or a small molecule capable of binding to TSP1.

### Claim 21 (depends on 1)

The method of claim 1, wherein the primary cells comprise endothelial cells, fibroblasts, hematopoietic cells, adipose cells, mucosal tissue cells, umbilical cord cells, or placenta cells.

### Claim 22 (depends on 21)

The method of claim 21, wherein the primary cells comprise human umbilical vein endothelial cells.

### Claim 23 (depends on 10)

A method for expanding differentiated cells, comprising:
generating differentiated cells by the method of claim 10; and
contacting the differentiated cells with an agent that blocks CD47 signaling, thereby expanding the differentiated cells.

### Claim 24

A method for expanding differentiated cells, comprising contacting the differentiated cells with an agent that blocks CD47 signaling.

### Claim 25 (depends on 1)

The method of claim 1, where cells are cultured continuously with an agent that blocks CD47 signaling.

### Claim 26 (depends on 1)

The method of claim 1, where cells are cultured transiently with an agent that blocks CD47 signaling.

### Claim 27 (depends on 1)

Cells produced by the method of claim 1.

### Claim 28

A method to increase stem cell numbers in an animal comprising administering to the animal an agent that blocks CD47 signaling.

### Claim 29 (depends on 28)

The method of claim 28, wherein the administering to the animal of an agent that blocks CD47 signaling comprises local administration of the agent or systemic administration of the agent.

### Claim 30 (depends on 28)

The method of claim 28, wherein the administering to the animal of an agent that blocks CD47 signaling comprises topical administration of the agent to the skin of the animal.

### Claim 31 (depends on 28)

The method of claim 28, wherein the agent that blocks CD47 signaling comprises an anti-CD47 antibody or fragment thereof, a CD47-binding peptide, a CD47 antisense oligonucleotide, a CD47 morpholino, an anti-TSP1 antibody or fragment thereof, a TSP1-binding peptide, a TSP1 antisense oligonucleotide, or a TSP1 morpholino.

### Claim 32 (depends on 31)

The method of claim 31, wherein the agent that blocks CD47 signaling comprises a small molecule capable of binding to CD47.

### Claim 33 (depends on 28)

The method of claim 28, wherein administering to the animal an agent that blocks CD47 signaling comprises parenteral administration.

### Claim 34 (depends on 1)

A method of treating a disorder in a subject comprising administering cells produced by the method of claim 1 to the subject.

### Claim 35 (depends on 34)

The method of claim 34, wherein the cells are administered to the subject parenterally.

### Claim 36 (depends on 35)

The method of claim 35, wherein the cells are administered to the subject by transplantation.

### Claim 37

A kit, comprising one or more of:
a container containing an agent that blocks CD47 signaling;
a container containing a cell culture medium; and
one or more cell culture dishes.

### Claim 38 (depends on 37)

The kit of claim 37, wherein the agent that blocks CD47 signaling comprises an anti-CD47 antibody or fragment thereof, a CD47-binding peptide, a CD47 antisense oligonucleotide, a CD47 morpholino, an anti-TSP1 antibody or fragment thereof, a TSP1-binding peptide, a TSP1 antisense oligonucleotide, or a TSP1 morpholino.

### Claim at position 39

39-41. (canceled)
